person · Reporting owner

Coric Vlad

Disclosed activity across 6 companies

Tapewire entity: 40505
SEC CIK: 0001704317

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Akili, Inc.DNAA · Entity 89130	Director	June 29, 2021	June 29, 2021
Biohaven Ltd.BHVN · Entity 4379	Director · Chief Executive Officer	February 27, 2026	March 03, 2026
Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269	Director · Chief Executive Officer	October 03, 2022	October 03, 2022
Royalty Pharma plcRPRX · Entity 3100	Director	June 05, 2026	June 08, 2026
Veradermics, IncMANE · Entity 1907	Director	February 03, 2026	February 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akili, Inc.

Report date June 29, 2021 · Filed June 29, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-06-29 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

Biohaven Ltd.

Report date February 27, 2026 · Filed March 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.52 · Expires 2036-02-27	Direct	550,000	Reported balance After 2026-02-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-27 · Grant · Acquired 550,000 · Balance 550,000 F1: The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Biohaven Pharmaceutical Holding Co Ltd.

Report date October 03, 2022 · Filed October 03, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	830,891	Reported balance After 2022-10-03 transaction · row 1 1 source row Row 1 · 2022-10-03 · Disposition to issuer · Disposed 92,050 · Balance 830,891 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
Common SharesSEC Table I · non-derivative	IndirectBy: The Vladimir Coric Marital Trust	517,391	Reported balance After 2022-10-03 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-10-03 · Disposition to issuer · Disposed 313,500 · Balance 517,391 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
Common SharesSEC Table I · non-derivative	IndirectBy 401(K) Plan	498,261	Reported balance After 2022-10-03 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-10-03 · Disposition to issuer · Disposed 19,130 · Balance 498,261 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
Common SharesSEC Table I · non-derivative	IndirectBy: The Vladimir Coric Family Trust	0	Reported balance After 2022-10-03 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2022-10-03 · Disposition to issuer · Disposed 498,261 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-03 · Disposition to issuer · Disposed 13,336 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-10-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-03 · Disposition to issuer · Disposed 13,336 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-10-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-03 · Disposition to issuer · Disposed 4,444 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-10-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-03 · Disposition to issuer · Disposed 4,444 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-10-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-03 · Disposition to issuer · Disposed 4,444 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-10-03 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-10-03 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-10-03 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-10-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-10-03 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-10-03 · Disposition to issuer · Disposed 10,950 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07	Direct	0	Reported balance After 2022-10-03 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-10-03 · Disposition to issuer · Disposed 775 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07	Direct	0	Reported balance After 2022-10-03 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2022-10-03 · Disposition to issuer · Disposed 69,225 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06	Direct	0	Reported balance After 2022-10-03 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2022-10-03 · Disposition to issuer · Disposed 2,398 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06	Direct	0	Reported balance After 2022-10-03 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2022-10-03 · Disposition to issuer · Disposed 97,602 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.99 · Expires 2029-11-25	Direct	0	Reported balance After 2022-10-03 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2022-10-03 · Disposition to issuer · Disposed 87,500 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2028-11-20	Direct	0	Reported balance After 2022-10-03 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2022-10-03 · Disposition to issuer · Disposed 196,916 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2028-11-20	Direct	0	Reported balance After 2022-10-03 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2022-10-03 · Disposition to issuer · Disposed 3,084 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.28 · Expires 2027-12-06	Direct	0	Reported balance After 2022-10-03 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2022-10-03 · Disposition to issuer · Disposed 19,240 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.28 · Expires 2027-12-06	Direct	0	Reported balance After 2022-10-03 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2022-10-03 · Disposition to issuer · Disposed 180,760 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2027-04-05	Direct	0	Reported balance After 2022-10-03 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2022-10-03 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.07 · Expires 2026-12-14	Direct	0	Reported balance After 2022-10-03 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2022-10-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.47 · Expires 2025-10-22	Direct	0	Reported balance After 2022-10-03 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2022-10-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.47 · Expires 2025-10-22	Direct	0	Reported balance After 2022-10-03 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2022-10-03 · Disposition to issuer · Disposed 75,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2024-11-25	Direct	0	Reported balance After 2022-10-03 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2022-10-03 · Disposition to issuer · Disposed 250,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Royalty Pharma plc

Report date June 05, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	15,343	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 15,343 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Veradermics, Inc

Report date February 03, 2026 · Filed February 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	33,706	Reported balance After 2026-02-05 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-02-05 · Conversion · Acquired 33,706 · Balance 33,706 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	33,706	Reported balance After 2026-02-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-02-05 · Conversion · Acquired 33,706 · Balance 33,706 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	182,500	Reported balance After 2026-02-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-02-05 · Conversion · Acquired 148,794 · Balance 182,500 F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	182,500	Reported balance After 2026-02-05 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-02-05 · Conversion · Acquired 148,794 · Balance 182,500 F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	260,575	Reported balance After 2026-02-05 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-02-05 · Conversion · Acquired 78,075 · Balance 260,575 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	260,575	Reported balance After 2026-02-05 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2026-02-05 · Conversion · Acquired 78,075 · Balance 260,575 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	319,398	Reported balance After 2026-02-05 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2026-02-05 · Purchase · Acquired 58,823 · Balance 319,398 F2: Shares held by Vladimir Coric Family Trust 2013.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	319,398	Reported balance After 2026-02-05 transaction · row 9 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 9 · 2026-02-05 · Purchase · Acquired 58,823 · Balance 319,398 F3: Shares held by Vladimir Coric Marital Trust 2013.
Common StockSEC Table I · non-derivative	Direct	129,939	Reported balance After 2026-02-05 transaction · row 7 1 source row Row 7 · 2026-02-05 · Conversion · Acquired 117,112 · Balance 129,939 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-02-05 · Conversion · Disposed 33,706 · Balance 0 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-02-05 · Conversion · Disposed 33,706 · Balance 0 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-02-05 · Conversion · Disposed 148,794 · Balance 0 F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-02-05 · Conversion · Disposed 148,794 · Balance 0 F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-05 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-02-05 · Conversion · Disposed 78,075 · Balance 0 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-05 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-02-05 · Conversion · Disposed 78,075 · Balance 0 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-02-05 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2026-02-05 · Conversion · Disposed 117,112 · Balance 0 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-02-03	Direct	51,525	Reported balance After 2026-02-03 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-02-03 · Grant · Acquired 51,525 · Balance 51,525 F6: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

Filing footnotes · ownership attribution and instrument terms

F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: Shares held by Vladimir Coric Family Trust 2013.

F3: Shares held by Vladimir Coric Marital Trust 2013.

F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F6: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Revance Therapeutics, Inc.

Report date February 04, 2025 · Filed February 06, 2025

Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2025-02-06 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-02-04 · Other · Disposed 5,784 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.

F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 03, 2022 Filed Oct 5, 2022 21:33 UTC	Biohaven Ltd. BHVN · Entity 4379	OtherCommon Shares	461,470	$0.00	$0.00	Disclosure SEC source: 0001562180-22-007074 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,470 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document
October 03, 2022 Filed Oct 12, 2022 22:31 UTC Amendment	Biohaven Ltd. BHVN · Entity 4379	OtherCommon Shares	0	$0.00	$0.00	Disclosure SEC source: 0001562180-22-007176 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,309 F1 · shares: Effective as of the pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares pursuant to the Separation and Distribution Agreement, dated as of May 9, 2022, by and among RemainCo, the Issuer and Pfizer Inc. ("Pfizer"), each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. (Cont'd in FN2) F2 · shares: (Cont'd from FN1) As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares. F3 · shares: This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 105,950 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares; however, as reflected in this amendment, 52,975 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. There were no other changes made to the information in the Original Form 4. Read SEC document
January 07, 2022 Filed Jan 7, 2022 21:16 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionRestricted Share Unit Award · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001562180-22-000350 · primarydocument.xml · derivative · entry 12 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F7 · derivative.exercise_date: The reporting person was granted 40,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document
January 07, 2022 Filed Jan 7, 2022 21:16 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantRestricted Share Unit Award · Derivative	40,000	$0.00	$0.00	Disclosure SEC source: 0001562180-22-000350 · primarydocument.xml · derivative · entry 11 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F7 · derivative.exercise_date: The reporting person was granted 40,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document
January 07, 2022 Filed Jan 7, 2022 21:16 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $128.87	$0.00	Disclosure SEC source: 0001562180-22-000350 · primarydocument.xml · derivative · entry 10 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires 2032-01-07 F6 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document
January 07, 2022 Filed Jan 7, 2022 21:16 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Tax withholdingCommon Shares	4,634	$128.87	$597,183.58	Disclosure SEC source: 0001562180-22-000350 · primarydocument.xml · nonDerivative · entry 4 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,584 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. F2 · balance_after: This balance includes 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2021. Read SEC document
January 07, 2022 Filed Jan 7, 2022 21:16 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	10,000	$0.00	$0.00	Disclosure SEC source: 0001562180-22-000350 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 06, 2022 Filed Jan 7, 2022 21:16 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionRestricted Share Unit Award · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0001562180-22-000350 · primarydocument.xml · derivative · entry 9 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 50,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document
January 06, 2022 Filed Jan 7, 2022 21:16 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Tax withholdingCommon Shares	5,854	$123.86	$725,076.44	Disclosure SEC source: 0001562180-22-000350 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,218 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document
January 06, 2022 Filed Jan 7, 2022 21:16 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	12,500	$0.00	$0.00	Disclosure SEC source: 0001562180-22-000350 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 26, 2021 Filed Feb 11, 2022 21:15 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	17,500	$0.00	$0.00	Disclosure SEC source: 0001562180-22-001433 · primarydocument.xml · nonDerivative · entry 4 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust Disclosed balance after: 313,500 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
November 26, 2021 Filed Feb 11, 2022 21:15 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	17,500	$0.00	$0.00	Disclosure SEC source: 0001562180-22-001433 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 452,500 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
November 25, 2021 Filed Nov 26, 2021 16:28 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionRestricted Share Unit Award · Derivative	10,950	$0.00	$0.00	Disclosure SEC source: 0001562180-21-007299 · primarydocument.xml · derivative · entry 7 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,950 Underlying: Common Shares · 10,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the issuer. F4 · derivative.exercise_date: The reporting person was granted 43,800 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document
November 25, 2021 Filed Nov 26, 2021 16:28 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Tax withholdingCommon Shares	5,075	$115.55	$586,416.25	Disclosure SEC source: 0001562180-21-007299 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,284 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document
November 25, 2021 Filed Nov 26, 2021 16:28 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	10,950	$0.00	$0.00	Disclosure SEC source: 0001562180-21-007299 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 21, 2021 Filed Feb 11, 2022 21:15 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	29,783	$0.00	$0.00	Disclosure SEC source: 0001562180-22-001433 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,355 Read SEC document
June 21, 2021 Filed Feb 11, 2022 21:15 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	29,783	$0.00	$0.00	Disclosure SEC source: 0001562180-22-001433 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric GRAT - 2019 Disclosed balance after: 70,217 Read SEC document
January 06, 2021 Filed Jan 8, 2021 20:48 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionRestricted Share Unit Award · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0001562180-21-000270 · primarydocument.xml · derivative · entry 9 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Shares · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F5 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F6 · derivative.exercise_date: The reporting person was granted 50,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. F7 · derivative.expiration_date: Not applicable. Read SEC document
January 06, 2021 Filed Jan 8, 2021 20:48 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantRestricted Share Unit Award · Derivative	50,000	$0.00	$0.00	Disclosure SEC source: 0001562180-21-000270 · primarydocument.xml · derivative · entry 8 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F5 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F6 · derivative.exercise_date: The reporting person was granted 50,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. F7 · derivative.expiration_date: Not applicable. Read SEC document
January 06, 2021 Filed Jan 8, 2021 20:48 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantEmployee Stock Option (right to buy) · Derivative	100,000	$0.00 Strike: $83.38	$0.00	Disclosure SEC source: 0001562180-21-000270 · primarydocument.xml · derivative · entry 7 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2031-01-06 F4 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document
January 06, 2021 Filed Jan 8, 2021 20:48 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Tax withholdingCommon Shares	5,802	$83.38	$483,770.76	Disclosure SEC source: 0001562180-21-000270 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,409 F2 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document
January 06, 2021 Filed Jan 8, 2021 20:48 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	12,500	$0.00	$0.00	Disclosure SEC source: 0001562180-21-000270 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance includes 741 shares that were acquired through the Biohaven Employee Share Purchase Plan on November 30, 2020. Read SEC document
November 25, 2020 Filed Nov 27, 2020 21:47 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionRestricted Share Unit Award · Derivative	10,950	$0.00	$0.00	Disclosure SEC source: 0001562180-20-006937 · primarydocument.xml · derivative · entry 7 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,900 Underlying: Common Shares · 10,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F4 · derivative.exercise_date: The reporting person was granted 43,800 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document
November 25, 2020 Filed Nov 27, 2020 21:47 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Tax withholdingCommon Shares	4,965	$90.14	$447,545.10	Disclosure SEC source: 0001562180-20-006937 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,970 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document
November 25, 2020 Filed Nov 27, 2020 21:47 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	10,950	$0.00	$0.00	Disclosure SEC source: 0001562180-20-006937 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 16, 2020 Filed Feb 12, 2021 21:51 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	2,500	$0.00	$0.00	Disclosure SEC source: 0001562180-21-001148 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust Disclosed balance after: 331,000 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
October 16, 2020 Filed Feb 12, 2021 21:51 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	2,500	$0.00	$0.00	Disclosure SEC source: 0001562180-21-001148 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 470,000 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
December 31, 2019 Filed Dec 31, 2019 19:33 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	100,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-006297 · primarydocument.xml · nonDerivative · entry 4 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,985 F1 · kind: These transactions consisted of (i) a gift by The Vladimir Coric Marital Trust of 100,000 common shares to the reporting person's spouse, (ii) a gift by the reporting person's spouse of such 100,000 shares to the reporting person and (iii) a change in form of beneficial ownership without a change of pecuniary interest (exempt from reporting under Rule 16a-13) of such 100,000 shares from direct ownership by the reporting person to beneficial ownership by the reporting person through The Vladimir Coric GRAT - 2019. Read SEC document
December 31, 2019 Filed Dec 31, 2019 19:33 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	100,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-006297 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F1 · kind: These transactions consisted of (i) a gift by The Vladimir Coric Marital Trust of 100,000 common shares to the reporting person's spouse, (ii) a gift by the reporting person's spouse of such 100,000 shares to the reporting person and (iii) a change in form of beneficial ownership without a change of pecuniary interest (exempt from reporting under Rule 16a-13) of such 100,000 shares from direct ownership by the reporting person to beneficial ownership by the reporting person through The Vladimir Coric GRAT - 2019. Read SEC document
December 31, 2019 Filed Dec 31, 2019 19:33 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	100,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-006297 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 100,000 F1 · kind: These transactions consisted of (i) a gift by The Vladimir Coric Marital Trust of 100,000 common shares to the reporting person's spouse, (ii) a gift by the reporting person's spouse of such 100,000 shares to the reporting person and (iii) a change in form of beneficial ownership without a change of pecuniary interest (exempt from reporting under Rule 16a-13) of such 100,000 shares from direct ownership by the reporting person to beneficial ownership by the reporting person through The Vladimir Coric GRAT - 2019. Read SEC document
December 31, 2019 Filed Dec 31, 2019 19:33 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	100,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-006297 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust Disclosed balance after: 340,000 F1 · kind: These transactions consisted of (i) a gift by The Vladimir Coric Marital Trust of 100,000 common shares to the reporting person's spouse, (ii) a gift by the reporting person's spouse of such 100,000 shares to the reporting person and (iii) a change in form of beneficial ownership without a change of pecuniary interest (exempt from reporting under Rule 16a-13) of such 100,000 shares from direct ownership by the reporting person to beneficial ownership by the reporting person through The Vladimir Coric GRAT - 2019. F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
December 27, 2019 Filed Mar 12, 2020 19:59 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	4,000	$0.00	$0.00	Disclosure SEC source: 0001562180-20-002440 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust Disclosed balance after: 333,500 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:39 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionRestricted Share Unit Award · Derivative	10,950	$0.00	$0.00	Disclosure SEC source: 0001689813-19-000128 · wf-form4_157689593372320.xml · derivative · entry 6 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,850 Underlying: Common Shares · 10,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F4 · derivative.exercise_date: The reporting person was granted 43,800 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:39 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Tax withholdingCommon Shares	4,965	$52.13	$258,825.45	Disclosure SEC source: 0001689813-19-000128 · wf-form4_157689593372320.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,985 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:39 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	10,950	$0.00	$0.00	Disclosure SEC source: 0001689813-19-000128 · wf-form4_157689593372320.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 27, 2019 21:29 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantRestricted Share Unit Award · Derivative	43,800	$0.00	$0.00	Disclosure SEC source: 0001689813-19-000106 · wf-form4_157490812958072.xml · derivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,800 Underlying: Common Shares · 43,800 shares Expires 2022-11-25 F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F2 · price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · derivative.exercise_date: The reporting person was granted 43,800 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. Read SEC document
November 25, 2019 Filed Nov 27, 2019 21:29 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantEmployee Stock Option (Right to Buy) · Derivative	87,500	$0.00 Strike: $57.40	$0.00	Disclosure SEC source: 0001689813-19-000106 · wf-form4_157490812958072.xml · derivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Shares · 87,500 shares Expires 2029-11-24 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on November 25, 2019, 2020, 2021 and 2022, subject to the optionholder's continuous service with the issuer at each vesting date. Read SEC document
August 15, 2019 Filed Mar 12, 2020 19:59 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	2,500	$0.00	$0.00	Disclosure SEC source: 0001562180-20-002440 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust Disclosed balance after: 337,500 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
August 15, 2019 Filed Mar 12, 2020 19:59 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	2,500	$0.00	$0.00	Disclosure SEC source: 0001562180-20-002440 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 472,500 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
June 26, 2019 Filed Jun 26, 2019 21:28 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	5,000	$40.22	$201,100.00	Disclosure SEC source: 0001209191-19-039193 · doc4.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(K) Plan Disclosed balance after: 19,130 Read SEC document
March 14, 2019 Filed Mar 14, 2019 17:49 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	15,783	$50.03	$789,623.49	Disclosure SEC source: 0001209191-19-019521 · doc4.xml · nonDerivative · entry 6 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust Disclosed balance after: 440,000 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 - $50.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 14, 2019 Filed Mar 14, 2019 17:49 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	16,110	$50.02	$805,822.20	Disclosure SEC source: 0001209191-19-019521 · doc4.xml · nonDerivative · entry 5 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 475,000 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 - $50.22,inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 13, 2019 Filed Mar 14, 2019 17:49 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	8,262	$50.02	$413,265.24	Disclosure SEC source: 0001209191-19-019521 · doc4.xml · nonDerivative · entry 4 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 455,783 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 - $50.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes to this Form 4. Read SEC document
March 13, 2019 Filed Mar 14, 2019 17:49 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	7,883	$50.02	$394,307.66	Disclosure SEC source: 0001209191-19-019521 · doc4.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 491,110 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 - $50.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes to this Form 4. Read SEC document
March 12, 2019 Filed Mar 14, 2019 17:49 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	25,955	$50.15	$1,301,643.25	Disclosure SEC source: 0001209191-19-019521 · doc4.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust 2013 Disclosed balance after: 464,045 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 - $50.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 12, 2019 Filed Mar 14, 2019 17:49 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	26,007	$50.15	$1,304,251.05	Disclosure SEC source: 0001209191-19-019521 · doc4.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Family Trust 2013 Disclosed balance after: 498,993 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 - $50.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
November 20, 2018 Filed Feb 14, 2019 16:32 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $32.42	$0.00	Disclosure SEC source: 0001209191-19-010174 · doc5.xml · derivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2028-11-19 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document
July 23, 2018 Filed Feb 14, 2019 16:32 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GiftCommon Shares	35,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-010174 · doc5.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust 2013 Disclosed balance after: 490,000 Read SEC document
June 01, 2018 Filed Jun 1, 2018 17:26 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	5,229	$35.04	$183,224.16	Disclosure SEC source: 0001209191-18-034777 · doc4.xml · nonDerivative · entry 6 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Marital Trust 2013 Disclosed balance after: 525,000 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 - $35.13, inclusive. Read SEC document
June 01, 2018 Filed Jun 1, 2018 17:26 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	8,611	$35.04	$301,729.44	Disclosure SEC source: 0001209191-18-034777 · doc4.xml · nonDerivative · entry 5 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Vladimir Coric Family Trust 2013 Disclosed balance after: 525,000 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 - $35.44, inclusive. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.